logo
#

Latest news with #Renza

Analysts Are Bullish on These NA Stocks: American Healthcare REIT, Inc. (AHR), CG Oncology, Inc. (CGON)
Analysts Are Bullish on These NA Stocks: American Healthcare REIT, Inc. (AHR), CG Oncology, Inc. (CGON)

Business Insider

time15-05-2025

  • Business
  • Business Insider

Analysts Are Bullish on These NA Stocks: American Healthcare REIT, Inc. (AHR), CG Oncology, Inc. (CGON)

There's a lot to be optimistic about in the NA sector as 2 analysts just weighed in on American Healthcare REIT, Inc. (AHR – Research Report) and CG Oncology, Inc. (CGON – Research Report) with bullish sentiments. Confident Investing Starts Here: American Healthcare REIT, Inc. (AHR) RBC Capital analyst Michael Carroll maintained a Buy rating on American Healthcare REIT, Inc. on May 13 and set a price target of $39.00. The company's shares closed last Wednesday at $34.19. According to Carroll is a 5-star analyst with an average return of 7.4% and a 59.6% success rate. Carroll covers the NA sector, focusing on stocks such as Easterly Government Properties, Diversified Healthcare Trust, and First Industrial Realty. American Healthcare REIT, Inc. has an analyst consensus of Strong Buy, with a price target consensus of $37.00, representing a 7.7% upside. In a report issued on April 28, Jefferies also initiated coverage with a Buy rating on the stock with a $37.00 price target. CG Oncology, Inc. (CGON) RBC Capital analyst Gregory Renza maintained a Buy rating on CG Oncology, Inc. on May 13 and set a price target of $68.00. The company's shares closed last Wednesday at $24.17, close to its 52-week low of $23.91. According to Renza is a 4-star analyst with an average return of 7.7% and a 40.3% success rate. Renza covers the Healthcare sector, focusing on stocks such as Perspective Therapeutics, Verrica Pharmaceuticals, and ACADIA Pharmaceuticals. The word on The Street in general, suggests a Strong Buy analyst consensus rating for CG Oncology, Inc. with a $60.25 average price target, implying a 150.1% upside from current levels. In a report issued on May 2, J.P. Morgan also initiated coverage with a Buy rating on the stock with a $41.00 price target.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store